Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.
A little more than a year since its last lead therapy bit the dust, Zalicus today reported that its new lead drug foundered in a pair of mid-stage studies and will join the company's growing scrap heap. The news triggered a rout on Wall Street, with shares in meltdown mode after the news hit.
Shares of already badly battered Coronado Biosciences stock took a fresh dive this morning after the biotech announced that the second mid-stage study of its experimental Crohn's drug had to be scrapped after independent monitors concluded that the therapy wasn't helping patients.
Shares of Geron doubled this morning after the company posted an abstract of promising results from a small study at the Mayo Clinic conducted on imetelstat for myelofibrosis.
With Sanofi having already begun enrollment for its 15,000-person Phase III trial, the French company has a clear lead in the race to develop a Clostridium difficile vaccine, but a growing pack is in pursuit. The latest to give chase is a group of European scientists with a new angle--they are developing an oral vaccine.
Ocera Therapeutics raised $28 million from a group of venture investors backing the biotech's work on orphan liver diseases. The San Diego-based biotech's lead therapy is OCR-002, ornithine phenylacetate, for the treatment of hepatic encephalopathy, which is slated to start a Phase IIb study later this year.
A competitor is threatening to chip away at sales of Merck's human papillomavirus vaccine Gardasil. Fortunately for Merck, it is the company developing the rival.
Keryx Biopharmaceuticals' shares jumped nearly 20% Tuesday morning on news that its chronic kidney disease drug Zerenex cleared a Phase II trial on nondialysis-dependent patients, possibly setting the stage for a broader indication once the much-scrutinized drug is approved.
ImmunoGen garnered considerable attention for the tech support role it played on Roche's armed antibody Kadcyla. But an attempt to steer one of its own antibody-drug conjugates through clinical studies ended in disaster today.
Merck may be playing catch-up in the race to develop the first all-oral combo treatment for hepatitis C, but it made a good case over the weekend that it has a real contender in the pipeline.